Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial.

Saved in:
Bibliographic Details
Title: Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial.
Authors: Kitahiro Y; Department of Pharmacy, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. ykitahi@med.kobe-u.ac.jp., Minami H; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan., Yamamoto K; Department of Pharmacy, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.; Department of Integrated Clinical and Basic Pharmaceutical Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan., Yakushijin K; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan., Kurata K; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan., Sakai R; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan., Saeki M; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan., Okazoe-Hirakawa Y; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan., Iida K; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan., Murase N; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan., Harima I; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan., Kitamura N; Department of Pharmacy, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan., Itohara K; Department of Pharmacy, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan., Omura T; Department of Pharmacy, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan., Sugimoto T; Department of Hematology and Oncology, Kita-Harima Medical Center, Ono, Japan., Takakura H; Department of Hematology and Oncology, Kita-Harima Medical Center, Ono, Japan., Kitao A; Department of Hematology and Oncology, Kita-Harima Medical Center, Ono, Japan., Takahashi M; Department of Pharmacy, Kita-Harima Medical Center, Ono, Japan., Shimoyama M; Department of Hematology and Oncology, Kohnan Medical Center, Kobe, Japan., Okuno M; Department of Pharmacy, Kohnan Medical Center, Kobe, Japan., Yano I; Department of Pharmacy, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Source: International journal of clinical oncology [Int J Clin Oncol] 2026 Jun; Vol. 31 (6), pp. 979-988. Date of Electronic Publication: 2026 Apr 16.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1437-7772
DOI:10.1007/s10147-026-03012-3